	US 11,833,168 B2
	Compounds and methods for increasing STMN2 expression
Huynh-Hoa Bui, San Diego, CA (US); Don W. Cleveland, La Jolla, CA (US); and Ze'ev Melamed, San Diego, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US); and Ludwig Institute For Cancer Research, Zurich (CH)
Appl. No. 16/973,652
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US); and Ludwig Institute For Cancer Research, Zurich (CH)
PCT Filed Jun. 14, 2019, PCT No. PCT/US2019/037215 § 371(c)(1), (2) Date Dec. 9, 2020, PCT Pub. No. WO2019/241648, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/685,192, filed on Jun. 14, 2018.
Prior Publication US 2021/0252039 A1, Aug. 19, 2021
Int. Cl. C12N 15/11 (2006.01); A61K 31/7125 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/7125 (2013.01) [C12N 15/113 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3181 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/344 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01)]

36 Claims

1. An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 15, at least 16, at least 17, or at least 18 consecutive nucleobases of a nucleobase sequence selected from SEQ ID NOs: 32, 33, 110, 188, 265, and 266, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage and/or at least one modified nucleoside comprising a modified sugar moiety.